| LncRNA Information | ||||||
|---|---|---|---|---|---|---|
| ID | EL0934 | Name | MRAK052686 | Aliases | N/A | |
| Species | Homo sapiens | Chromosome | N/A | Start site | N/A | |
| End site | N/A | Chain | N/A | Exon NO. | N/A | |
| Assembly | N/A | Class | N/A | NCBI accession | N/A | |
| Ensembl | N/A | Sequence | N/A | |||
| Disease | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Disease | Method | Sample | Expression pattern | Dysfunction type | Description | PMID | Source | ||
| Nonalcoholic fatty liver disease | N/A | N/A | N/A | N/A | Berberine ameliorates nonalcoholic fatty liver disease by a global modulation of hepatic mRNA and lncRNA expression profiles. MRAK052686, was found strongly correlated with the antioxidant factor Nrf2, and both genes were down-regulated by the steatotic liver. The reduced expression of MRAK052686 and Nrf2 was completely reversed by BBR treatment, suggesting a new mechanism accounting for the therapeutic effect of BBR. | 25623289 | LncRNADisease | ||